FDA Approves Ringer's In Plastic Container (Ringer's solution) for parenteral replacement of extracellular fluid and electrolyte losses.
The FDA has approved Ringer's In Plastic Container, a sterile solution, for the parenteral replacement of extracellular losses of fluid and electrolytes. The indication is broad, intended for use as required by the clinical condition of the patient, and the solution may include minimal carbohydrate calories. This approval provides a standard intravenous option for managing fluid and electrolyte deficits in various clinical settings. Clinicians should note specific warnings regarding its use in patients with conditions like hyperkalemia, congestive heart failure, or severe renal insufficiency due to its sodium, potassium, calcium, and lactate content. Careful administration is required to avoid fluid or solute overload, and the solution must not be infused simultaneously with blood through the same set due to the risk of coagulation from its calcium ions.
＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)
Not reported in label.
This solution is indicated for parenteral replacement of extracellular losses of fluid and electrolytes, with or without minimal carbohydrate calories, as required by the clinical condition of the patient.
The dose is dependent upon the age, weight and clinical condition of the patient. Additives may be incompatible; consult with a pharmacist if available. When introducing additives, use aseptic technique, mix thoroughly and do not store. The presence of calcium limits compatibility with certain drugs that form precipitates of calcium salts and prohibits simultaneous infusion through the same administration set as blood because of the likelihood of coagulation. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Trial data not available in label.
Solutions containing calcium ions should not be administered simultaneously through the same administration set as blood because of the likelihood of coagulation. Solutions which contain potassium should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present. Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. In patients with diminished renal function, administration of solutions containing sodium or potassium ions may result in sodium or potassium retention. Solutions containing lactate ions should be used with great care in patients with metabolic or respiratory alkalosis and where there is an increased level or an impaired utilization of lactate ions, as in severe hepatic insufficiency. The intravenous administration can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of administered parenteral solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.
Not reported in label.